Vertical: CNMBase Year: 2025
Market Size (2025)
$208.76M
Projected (2032)
$296.41M
CAGR (2022–2032)
5.1%
Key Players
8+
Market Overview
The global ionophores market was valued at USD 208.764 million in 2025 and is projected to reach USD 296.414 million by 2032, registering a CAGR of 5.13% over 2026–2032. The market has expanded steadily from USD 179.591 million in 2022, and is expected to add USD 87.650 million in absolute value between 2025 and 2032.
Ionophores are carboxylic polyether antibiotics produced by fermentation of Streptomyces and related actinomycetes. In animal production they are used mainly in two ways: as in-feed anticoccidials that control Eimeria infections in broiler chickens and turkeys, and as rumen modifiers that improve feed efficiency and reduce digestive disorders such as bloat and acidosis in beef and dairy cattle. Because ionophores have no use in human medicine, regulators in the United States, the European Union, Australia and China treat them separately from medically important antimicrobials. This has allowed them to remain a core tool for coccidiosis control while antibiotic growth promoters have been withdrawn in the European Union (2006), China (2020) and, under a 2026 ordinance, Brazil.
Demand is tied directly to the scale of animal protein production. USDA Foreign Agricultural Service estimates place world chicken meat production at about 112.4 million tonnes in 2026, with a forecast of about 114.9 million tonnes for 2027, while global beef production is expected to remain close to 60 million tonnes. Coccidiosis remains one of the most costly diseases in commercial poultry; a 2020 study published in Veterinary Research estimated its global cost in chickens at about GBP 10.4 billion at 2016 prices.
Key Findings
Largest product type: Monensin accounted for USD 73.067 million in 2025, a 35.0% share, and is projected to reach USD 101.061 million by 2032.
Fastest-growing product type: Narasin is expected to grow at the highest CAGR of 6.21%, rising from USD 31.315 million in 2025 to USD 47.757 million in 2032.
Livestock: Poultry is both the largest and the fastest-growing livestock segment, with USD 125.258 million (60.0%) in 2025 and a CAGR of 5.55%, compared with 4.49% for cattle.
Leading and fastest-growing region: Asia Pacific held USD 87.681 million (42.0%) in 2025 and is projected to grow at 6.06%, the highest among all regions, reaching USD 132.378 million by 2032.
Leading country: China is the largest country market at USD 40.333 million in 2025, equal to 19.3% of the global market, followed by the U.S. at USD 29.310 million and Brazil at USD 21.419 million.
Fastest-growing country: India is projected to post the highest country-level CAGR of 7.45%, followed by Saudi Arabia at 7.02%.
Mature markets: Europe (3.54%) and North America (3.75%) are the slowest-growing regions. North America and Latin America each held USD 37.578 million in 2025, but Latin America is expected to grow faster, at 5.22%.
Segmentation Summary
The market is segmented by product type (Monensin, Salinomycin, Narasin and Others), by livestock (Poultry and Cattle) and by region (North America, Europe, Asia Pacific, Latin America and Middle East & Africa), with country-level estimates for 20 country and sub-regional markets. Monensin leads because it is used in both cattle and poultry, while salinomycin and narasin are used mainly in broiler anticoccidial programmes and are gaining share as poultry production expands. In 2025, Salinomycin and the Others category (lasalocid, maduramicin, semduramicin and other ionophores) each accounted for USD 52.191 million, or 25.0% of the market.
Competitive Landscape Summary
The finished-product segment of the market is moderately consolidated. Elanco Animal Health (Rumensin, Coban, Monteban, Maxiban), Phibro Animal Health (Coxistac, Aviax, Avatec, Bovatec, Cygro) and Huvepharma (Sacox, Bio-Cox, Coxidin, Monimax) hold the strongest brand portfolios and regulatory registrations across major markets. Phibro’s acquisition of the Zoetis medicated feed additive portfolio, completed on 31 October 2024, further concentrated the branded segment. Active pharmaceutical ingredient supply is more fragmented, with Chinese fermentation producers such as Jinhe Biotechnology, Shandong Qilu King-Phar Pharmaceutical, Shandong Shengli Bioengineering and Zhejiang Shenghua Biok Biology supplying monensin and salinomycin to domestic and export markets. Regional animal health companies such as Virbac participate in selected markets.
Challenges and Opportunities
The main challenges are the continued classification of ionophores as antibiotics for “raised without antibiotics” label claims, the narrow safety margin of ionophores in non-target species such as horses and dogs, the gradual development of Eimeria resistance, and price competition from generic fermentation-based supply. Growth opportunities lie in the expansion of commercial poultry production in Asia Pacific, the Middle East and Africa; the move by several large U.S. poultry companies from “No Antibiotics Ever” programmes to “No Antibiotics Important to Human Medicine” standards, which permit ionophores; the withdrawal of non-ionophore growth promoters in markets such as Brazil; and the positioning of cattle ionophores within feed-efficiency and emissions-intensity programmes.
Future Outlook
The market is projected to grow from USD 219.498 million in 2026 to USD 296.414 million in 2032. Growth will be led by poultry applications and by emerging regions: Asia Pacific is expected to add USD 44.697 million between 2025 and 2032, more than half of the global absolute increase of USD 87.650 million. In mature markets, growth will depend on regulatory renewals, rotation and shuttle programmes that combine ionophores with chemical anticoccidials and vaccines, and steady use in feedlot and dairy cattle. Over the forecast period, narasin and salinomycin are expected to gain share from monensin and from the Others category, reflecting the higher growth of broiler production relative to cattle.
The Ionophores Market market is projected to grow at a CAGR of 5.1% from 2022 to 2032.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansDefinition
Ionophores are lipid-soluble carboxylic polyether antibiotics that bind metal cations and transport them across biological membranes. By disturbing the sodium, potassium and hydrogen ion gradients of susceptible cells, they kill or inhibit the extracellular stages (sporozoites and merozoites) of Eimeria parasites in the poultry gut and suppress gram-positive bacteria in the rumen. In cattle, this shifts rumen fermentation towards propionate production, improving feed conversion and reducing the risk of bloat and lactic acidosis. Ionophores are produced by fermentation: monensin from Streptomyces cinnamonensis, salinomycin from Streptomyces albus, narasin from Streptomyces aurofaciens, lasalocid from Streptomyces lasaliensis, and maduramicin and semduramicin from Actinomadura species.
For the purpose of this study, the ionophores market covers the value of ionophore products sold for use in poultry and cattle, including active ingredients formulated as premixes, granular feed additives, medicated feed concentrates and intraruminal devices, as well as fixed combination products in which an ionophore is the primary active ingredient (for example, narasin with nicarbazin). The market is measured at the level of manufacturer sales.
Included: monensin, salinomycin, narasin and other ionophores (lasalocid, maduramicin, semduramicin, laidlomycin and similar compounds) used in poultry and cattle for coccidiosis control, feed efficiency, and the prevention of related digestive and metabolic disorders.
Excluded: synthetic chemical anticoccidials used alone (such as nicarbazin, diclazuril, decoquinate, robenidine and amprolium), live and attenuated coccidiosis vaccines, non-ionophore antibiotics and growth promoters, phytogenic and probiotic feed additives, ionophores used in species other than poultry and cattle, and ionophores sold for laboratory, research or human pharmaceutical purposes.
Scope of the Study
The study provides market estimates and forecasts for the global ionophores market by product type, livestock and region, with country-level analysis for each region. Historical data covers 2022–2024, 2025 is the base year, and forecasts cover 2026–2032. All values are in USD Million.
Research Objectives
To estimate the size of the global ionophores market in value terms for 2022–2025 and forecast it for 2026–2032.
To analyse the market by product type (Monensin, Salinomycin, Narasin and Others) and by livestock (Poultry and Cattle).
To assess regional and country-level demand across North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
To identify the drivers, restraints, opportunities and trends affecting ionophore use in poultry anticoccidial programmes and cattle feeding.
To evaluate the effect of antimicrobial stewardship policy, feed additive authorisation rules and food labelling standards on ionophore demand.
To map the value chain from fermentation-based active ingredient production to integrators, feed mills, feedlots and dairy farms.
To profile the competitive environment, including the positioning of leading companies and key developments since 2022.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansOverview of the Research Process
The study followed a structured process combining secondary research, primary research, market size estimation and forecasting. Secondary research established the market definition, product landscape, regulatory framework and baseline indicators of livestock production. Primary research was used to test assumptions on usage patterns, pricing, product mix and regional demand. Market size was then estimated using top-down and bottom-up approaches, reconciled through data triangulation, and projected over 2026–2032 using a factor-based forecasting model.
Step 1 – Market definition and scoping: definition of ionophore products, livestock applications and geographic coverage.
Step 2 – Secondary research: collection of production, regulatory, company and trade data.
Step 3 – Primary research: discussions with supply-side and demand-side participants to validate findings.
Step 4 – Market estimation: top-down and bottom-up estimates, triangulated to arrive at the base-year market size.
Step 5 – Forecasting and validation: projection of segment, regional and country values and internal consistency checks.
Secondary Research
Secondary research drew on sources specific to animal health, feed additives and livestock production, including:
Government and regulatory bodies: the U.S. Food and Drug Administration Center for Veterinary Medicine (antimicrobial sales and distribution reports, approved animal drug listings), USDA Foreign Agricultural Service and Food Safety and Inspection Service, the European Food Safety Authority, the European Commission’s EU Register of Feed Additives, the U.K. Veterinary Medicines Directorate, the Canadian Food Inspection Agency, the Australian Pesticides and Veterinary Medicines Authority, Brazil’s Ministry of Agriculture and Livestock, and China’s Ministry of Agriculture and Rural Affairs.
Intergovernmental organisations: the Food and Agriculture Organization of the United Nations and the OECD-FAO Agricultural Outlook for poultry and beef production and consumption.
Industry associations: national poultry and cattle producer associations, feed manufacturer associations and animal health industry bodies.
Company filings: annual reports, Form 10-K filings, investor presentations and press releases of animal health and feed additive companies.
Trade journals and scientific literature: poultry, feed and veterinary publications, and peer-reviewed studies on coccidiosis control, anticoccidial resistance and rumen modification.
Paid databases: trade statistics, company databases and livestock market databases.
Primary Research
Primary research was conducted through in-depth interviews and structured discussions with participants across the value chain. Its objectives were to validate the market definition and segmentation, confirm product usage patterns and dosing practices, obtain views on pricing and product mix, and assess the expected effect of regulatory changes and alternative coccidiosis control methods on demand.
Supply side: manufacturers of ionophore active ingredients and premixes, animal health product managers, regulatory affairs specialists, distributors and premix producers.
Demand side: poultry integrators, nutritionists and veterinarians, commercial feed mill managers, feedlot operators, dairy nutrition consultants and livestock producer association representatives.
Market Size Estimation
Top-down approach: the overall animal health and medicated feed additive market was used as a starting point, and the share attributable to ionophores was derived from company disclosures, product portfolio analysis and regulatory sales data. The resulting value was allocated to product types, livestock segments, regions and countries.
Bottom-up approach: demand was built from livestock populations and production volumes (broiler and turkey production, cattle on feed and dairy herds), adjusted for the proportion of animals receiving ionophores, typical inclusion rates and treatment duration, and average selling prices by product and region. Country estimates were aggregated to regional and global totals.
Data triangulation: the results of the two approaches were compared and reconciled with company-level revenue indications and primary research inputs. Differences were resolved by reviewing assumptions on adoption rates, pricing and product mix until the estimates converged.
Forecasting Methodology
Forecasts were developed for each country and segment and aggregated to regional and global levels. The model considered:
Projected poultry meat and cattle production by country and region.
Penetration of ionophores in broiler, turkey, feedlot and dairy programmes, and the expected effect of rotation and shuttle programmes and vaccine use.
Regulatory developments, including feed additive authorisations and renewals, antimicrobial classification and food labelling standards.
Price trends for active ingredients and finished products, including the effect of generic competition.
Macroeconomic factors such as income growth, urbanisation, feed grain prices and trade in animal protein.
Each factor was assessed for its expected impact over 2026–2027, 2028–2030 and 2031–2032, and the resulting growth rates were applied to base-year values. Forecasts were checked for consistency across segmentations so that segment, regional and country values sum to the global total in every year.
Base Year, Forecast Period and Currency
Assumptions and Limitations
Ionophores will remain classified as not medically important antimicrobials in major markets throughout the forecast period.
No major outbreak of animal disease (such as highly pathogenic avian influenza) will cause a prolonged, multi-year contraction in regional poultry production.
Existing feed additive authorisations for the main ionophores will be renewed in the European Union and other markets that apply periodic re-evaluation.
Values are expressed at manufacturer level; distributor and feed mill margins are excluded.
Company revenues are often not reported at ionophore level, so segment values rely on estimation and triangulation.
Country data for smaller markets grouped under “Rest of” categories is based on regional ratios and is subject to a higher margin of error.
Base Year
2025
Historical Period
2022 – 2024
Forecast Period
2026 – 2032
Primary Interviews
150+
Historical data (2022–2025) and forecast period (2025–2032)
Our research process spans primary interviews with industry stakeholders combined with comprehensive secondary data analysis, validated through triangulation across multiple independent sources.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansIntroduction
The global ionophores market has a two-tier structure. The branded finished-product segment, particularly in regulated markets such as the U.S., the EU, Canada and Australia, is moderately consolidated: a small number of companies hold the product registrations, feed additive authorisations and technical service networks required to supply large integrators and feed mills. The active ingredient and generic premix segment is more fragmented, with several fermentation-based producers in China supplying domestic demand and export markets in Asia, Latin America, the Middle East and Africa.
Most ionophores are off-patent, so competition is based on cost of production, supply reliability, regulatory status, product breadth and technical support rather than on patent protection. Leading suppliers defend their positions by maintaining registrations in many countries, offering combination products and complete coccidiosis control portfolios, and investing in fermentation efficiency. Consolidation has increased since 2024, when Phibro acquired the Zoetis medicated feed additive portfolio and Zoetis exited the category.
Key Player Positioning
Leaders – Elanco Animal Health, Phibro Animal Health and Huvepharma. These companies hold the broadest ionophore portfolios and the strongest registration positions in regulated markets. Elanco is the leading supplier of monensin and narasin, with brands such as Rumensin, Coban, Monteban and Maxiban, and produces monensin and narasin at its fermentation site in Clinton, Indiana. Its farm animal business reported revenue of USD 2,362 million in 2025, including USD 1,125 million from cattle and USD 858 million from poultry. Phibro has the widest range of ionophores, covering salinomycin, semduramicin, lasalocid and maduramicin, and its fiscal 2026 “MFAs and other” sales grew 25% to USD 810.7 million, including the acquired Zoetis portfolio. Huvepharma, a privately held Bulgarian group, is the main salinomycin supplier in Europe and the U.S. and markets monensin and combination products alongside chemical anticoccidials and vaccines.
Challengers – Jinhe Biotechnology, Shandong Qilu King-Phar Pharmaceutical, Shandong Shengli Bioengineering and Zhejiang Shenghua Biok Biology. These Chinese producers manufacture monensin and salinomycin by fermentation and supply active ingredients and premixes at competitive prices. Jinhe Biotechnology, a listed company best known for chlortetracycline, includes salinomycin and monensin in its veterinary chemicals line. Shandong Shengli Bioengineering is a joint venture between China Animal Husbandry Industry Co., Ltd. and Shandong Shengli Co., Ltd., producing animal-specific antibiotic active ingredients including monensin and salinomycin. Their strength lies in scale and cost; their presence in regulated Western markets is limited by registration requirements.
Niche players – Virbac and regional formulators. Virbac, a global animal health company with a strong companion animal and ruminant business, markets the salinomycin product Virbacox in selected African markets. Regional formulators and distributors in India, Southeast Asia and Latin America sell generic ionophore premixes under local brands.
Threat of New Entrants: Low
Large-scale fermentation and recovery facilities require significant capital investment and process know-how.
Each product needs separate approval or feed additive authorisation in each market, and EU authorisations must be renewed every ten years with updated safety and efficacy data.
Established suppliers have long-term relationships with integrators and feed mills and provide technical service that new entrants find difficult to match.
Bargaining Power of Suppliers: Low to Medium
Fermentation inputs such as starch, glucose and soybean meal are widely available commodities.
Active ingredient production is concentrated in a limited number of fermentation plants, many of them in China, which gives some leverage to integrated producers.
Vertically integrated companies such as Elanco and Huvepharma reduce their dependence on external active ingredient suppliers.
Bargaining Power of Buyers: High
Poultry integrators, large feed mills and feedlots purchase large volumes and negotiate annual contracts.
Most ionophores are off-patent, and generic premixes are available in many markets.
Buyers can switch between ionophores and chemical anticoccidials within rotation programmes.
Threat of Substitutes: Medium
Chemical anticoccidials (such as nicarbazin, diclazuril and decoquinate) and live coccidiosis vaccines are established alternatives in poultry.
Phytogenic additives, probiotics and other alternatives are being promoted for antibiotic-free programmes, though their efficacy is less consistent.
In cattle, few substitutes deliver comparable feed-efficiency gains at similar cost, which limits substitution in feedlot rations.
Competitive Rivalry: High
Competition among branded suppliers and generic producers is based on price, supply reliability and technical support.
Leading companies defend share through registrations, combination products and full coccidiosis portfolios.
Consolidation, such as Phibro’s acquisition of the Zoetis portfolio, is increasing the scale of the main competitors.
Threat of New Entrants: Low; Fermentation scale, product-specific registrations and long renewal cycles limit entry into regulated markets.
Bargaining Power of Suppliers: Low to Medium; Fermentation inputs are commodities, but active ingredient production is concentrated among a limited number of producers.
Bargaining Power of Buyers: High; Integrators, large feed mills and feedlots buy in large volumes and can switch between branded and generic products.
Threat of Substitutes: Medium; Chemical anticoccidials, vaccines and non-antibiotic alternatives can replace ionophores in some programmes.
Competitive Rivalry: High; Products are largely off-patent and competition focuses on price, supply reliability and technical service.
Market estimates by geography (2032)
InsightAsia Pacific leads with $132.38M by 2032.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription Plans| REGION | 2022 | 2025 | 2032 | CAGR | SHARE |
|---|---|---|---|---|---|
| North America | $33.58M | $40.48M | $48.64M | 3.8% | 16% |
| Europe | $28.16M | $33.60M | $39.97M | 3.6% | 13% |
| Asia Pacific | $73.36M | $98.69M | $132.38M | 6.1% | 45% |
| Latin America | $32.20M | $41.63M | $53.67M | 5.2% | 18% |
| Middle East & Africa | $12.30M | $16.38M | $21.76M | 5.9% | 7% |
| Total | $179.59M | $230.78M | $296.41M | 5.1% | 100% |
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansTotal Market Size
$296.41M
| APPLICATION | REVENUE ($B) | GROWTH RATE | MARKET PENETRATION |
|---|---|---|---|
| Monensin | $101.06M | 4.8% | 34% |
| Salinomycin | $77.42M | 5.8% | 26% |
| Others | $70.18M | 4.3% | 24% |
| Narasin | $47.76M | 6.2% | 16% |
* Revenue projections based on 2025 estimates. Growth rates represent CAGR 2024–2030. Market penetration indicates current adoption rate within addressable market segments.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSee plans for professionals or small and medium businesses.
Analytical insights on Ionophores Market covering market dynamics, competitive landscape, and strategic outlook.
The Ionophores Market market is projected to reach $296.41M by 2032, growing at 5.1% CAGR. The Monensin segment holds the largest share.
Demand for ionophores is shaped by the scale and intensity of poultry and cattle production, the economics of feed conversion, the regulatory treatment of antimicrobials in animal feed, and the availability of alternative coccidiosis control methods. Because ionophores are used in nearly every intensive broiler system and in most feedlot rations where they are permitted, the market tends to grow in line with livestock output rather than through new applications. Regulation acts in both directions: restrictions on medically important antimicrobials and on non-ionophore growth promoters tend to support ionophore use, while “raised without antibiotics” programmes and tighter feed additive re-evaluation work against it.
Expansion of Global Poultry Meat Production
Poultry is the largest and fastest-growing source of meat worldwide, and almost all intensive broiler production relies on in-feed anticoccidials. USDA Foreign Agricultural Service estimates world chicken meat production at about 112.4 million tonnes in 2026 and forecasts about 114.9 million tonnes in 2027, an increase of roughly 2%. The OECD-FAO Agricultural Outlook 2026–2035 projects that poultry will account for the largest absolute increase in meat consumption over the next decade. Most of this growth is expected in Asia, Latin America, the Middle East and Africa, where production is moving from backyard flocks to integrated, high-density systems in which Eimeria challenge is higher and preventive coccidiosis control becomes standard practice.
Ionophores remain the most widely used drugs for this purpose. A 2019 review in Parasitology Research described ionophores as the most extensively used anticoccidials in poultry and reported that they account for more than 70% of the antimicrobials used for coccidia control in the United Kingdom. As integrators expand capacity, ionophore demand rises with the number of birds placed, which explains why the poultry segment is projected to grow faster than cattle.
Feed-Efficiency Economics in Beef and Dairy Cattle
In cattle, ionophores such as monensin and lasalocid alter rumen fermentation, increasing propionate production and reducing energy losses as methane and heat. The result is improved feed conversion, better weight gain on forage and concentrate diets, and a lower incidence of bloat, lactic acidosis and coccidiosis. Feed is the largest cost item in feedlot and dairy operations, so even small improvements in conversion efficiency have a direct effect on margins.
The importance of these products to cattle producers is reflected in supplier disclosures. Elanco lists Rumensin (monensin) among its top five products, and its 2025 annual report states that 89% of its revenue from animal-only antibiotics came from ionophores. In North America, Argentina, Brazil and Australia, where feedlot finishing is widespread, ionophores are a standard component of rations. High cattle prices and tight herd numbers in several markets increase the value of feed-efficiency gains, supporting continued use even when cattle numbers are not growing.
Regulatory Classification as Not Medically Important Antimicrobials
Ionophores are not used in human medicine and show no cross-resistance with antibiotic classes used in people. As a result, regulators place them outside the controls applied to medically important antimicrobials. The U.S. FDA classifies ionophores as “not medically important” in its annual antimicrobial sales reports; in 2020, ionophore sales for food animals amounted to 3,619,265 kg of active ingredient, about 35% of all antimicrobials sold for food-producing animals in the U.S. The revised FDA Guidance for Industry #152, finalised in August 2026, maintains this approach. Ionophores are therefore not subject to the Veterinary Feed Directive and remain available for over-the-counter use in medicated feed.
Similar treatment applies elsewhere. In the European Union, coccidiostats are authorised as a separate category of feed additives under Regulation (EC) No 1831/2003, even though growth-promoting uses of monensin and salinomycin were withdrawn in 2006. Australia’s ASTAG rates the main ionophores as of “low” importance to human health. In China, MARA Announcement No. 194 removed growth-promoting drug feed additives from 2020 but allowed anticoccidials to continue in feed under veterinary drug approval numbers. As medically important antimicrobials face tighter controls, ionophores remain one of the few antimicrobial classes that producers can continue to use routinely.
Shift from “No Antibiotics Ever” to “No Antibiotics Important to Human Medicine”
Over the past decade, many U.S. poultry companies adopted “No Antibiotics Ever” (NAE) programmes, which also exclude ionophores because USDA treats them as antibiotics for labelling purposes. These programmes raised mortality and production costs in some flocks, as producers had to rely on vaccines and chemical anticoccidials alone. In July 2023, Tyson Foods announced that it would move its branded chicken from NAE to a “No Antibiotics Important to Human Medicine” (NAIHM) standard, which allows ionophores, with the transition planned for completion by the end of 2023. Chick-fil-A announced a similar move to NAIHM from spring 2024.
These decisions by two of the largest buyers and producers of chicken in the U.S. re-opened a significant volume of broiler production to ionophore use. They also show that animal welfare and production efficiency are now weighed alongside consumer labelling preferences in antibiotic policy. If other integrators and food service chains follow, ionophore demand in the U.S. broiler sector could recover part of the volume lost during the expansion of NAE programmes.
Poultry Expansion in Asia Pacific, the Middle East and Africa
Asia Pacific is the largest and fastest-growing regional market, projected to grow at 6.06% over 2026–2032, while Middle East & Africa is projected to grow at 5.85%. Commercial broiler production in India, Southeast Asia, Saudi Arabia and Sub-Saharan Africa is expanding as incomes rise and governments promote domestic food production. These markets are moving from smallholder systems to integrated operations with professional nutrition and veterinary support, which increases the use of preventive anticoccidials. Suppliers that build distribution, registrations and technical service in these markets are well placed to capture the incremental volume.
Feed Efficiency and Emissions Intensity in Cattle
Ionophores reduce the share of feed energy lost as methane and improve feed conversion, which lowers the emissions intensity of beef and milk production. Although the reduction in methane is moderate compared with dedicated methane inhibitors, ionophores are already approved, inexpensive and widely used, which makes them part of low-cost emissions-intensity strategies. Suppliers are increasingly combining ionophores with other cattle sustainability products; Elanco, for example, distributes the methane-reducing feed ingredient Bovaer alongside Rumensin. This positioning may support demand in markets where processors and retailers are setting supply chain emissions targets.
Withdrawal of Non-Ionophore Growth Promoters
Where regulators restrict antibiotic growth promoters that are not ionophores, producers often increase reliance on ionophores to maintain gut health and performance. In Brazil, Portaria SDA/MAPA No. 1.617 of April 2026 banned avoparcin, bacitracin, zinc bacitracin, bacitracin methylene disalicylate and virginiamycin as growth-promoting feed additives, with a 180-day transition; ionophores were not included in the ban. Brazil is one of the largest poultry and beef producers in the world, so this change creates an opportunity for ionophore suppliers to expand use in broiler and feedlot programmes. Similar shifts may occur in other markets reviewing growth promoter policy.
“Raised Without Antibiotics” Claims and Consumer Perception
Although ionophores are not used in human medicine, they are antibiotics in a technical sense, and food labelling rules generally treat them as such. In 2007, USDA required Tyson to remove a “raised without antibiotics” claim because its feed contained ionophores, establishing that NAE products cannot use ionophores. Retailers and restaurant chains that market antibiotic-free meat continue to exclude ionophores from their supply chains. Consumer concern about antibiotic use in livestock, and the difficulty of explaining the difference between ionophores and medically important antibiotics, limits ionophore penetration in premium and branded meat segments in the U.S. and some European markets.
Toxicity to Non-Target Species and Cross-Contamination Controls
Ionophores have a narrow safety margin in some species. The reported median lethal dose of monensin is about 2–3 mg/kg body weight in horses, compared with 20–80 mg/kg in cattle, and there is no specific antidote. Cases of accidental poisoning, such as the deaths of horses in Minnesota in 2018 after monensin carry-over from cattle feed, have led to strict rules on feed manufacturing. In the U.S., 21 CFR 225.65 requires cleanout, flushing and sequencing procedures, and in the EU, Regulation (EC) No 124/2009 and Directive 2009/8/EC set maximum levels of coccidiostats in non-target feed and food. In May 2024, the European Commission suspended the marketing authorisation of Kexxtone, Elanco’s monensin intraruminal device for dairy cows, after regurgitated devices caused fatal exposure in dogs. These controls add compliance costs for feed mills and limit the use of ionophores in mixed-species operations.
Eimeria Resistance and Alternative Control Methods
Prolonged use of any anticoccidial selects for resistant Eimeria strains. Resistance to ionophores develops more slowly than to most chemical anticoccidials, but reduced sensitivity is widespread in long-established broiler industries. The EU renewal of Huvepharma’s Coxidin (monensin) in March 2026 required post-market monitoring because signs of Eimeria resistance had been observed. Producers respond by rotating products or combining them with live coccidiosis vaccines, which reduces the number of grow-out cycles in which ionophores are used. Phytogenic additives, probiotics and other non-antibiotic alternatives are also being promoted for coccidiosis management, particularly in antibiotic-free programmes.
Consolidation of Medicated Feed Additive Portfolios
The branded medicated feed additive segment is consolidating around a few specialised suppliers. Phibro Animal Health completed its acquisition of the Zoetis medicated feed additive portfolio and certain water-soluble products on 31 October 2024, under an agreement announced in April 2024 at USD 350 million; Phibro’s fiscal 2026 annual report records the purchase consideration at about USD 297.5 million after adjustments. Zoetis has since stated that medicated feed additives are no longer one of its major product categories. Large diversified animal health companies are focusing on companion animal and biologic products, while specialists such as Phibro and Huvepharma are building scale in feed additives.
Rotation, Shuttle and Bio-Shuttle Programmes
Coccidiosis control is increasingly managed as a programme rather than a single product decision. Rotation of ionophores with chemical anticoccidials between flocks, shuttle programmes that use different products in starter and grower feeds, and bio-shuttle programmes that start with a live vaccine and finish with an ionophore are now standard in many broiler industries. These programmes help maintain ionophore efficacy over the long term and create demand for suppliers that offer a broad portfolio of ionophores, chemicals and vaccines with technical support.
Reliance on Chinese Fermentation Capacity and Price Pressure
Most ionophores are off-patent, and a significant share of global monensin and salinomycin active ingredient is produced by fermentation in China. Producers such as Jinhe Biotechnology have added fermentation and chemical capacity, which supports supply but also increases price competition. Buyers in price-sensitive markets can source generic premixes at lower cost than branded products, putting pressure on margins. At the same time, reliance on a concentrated supply base exposes the market to disruptions from environmental inspections, energy costs and trade measures.
Stricter Re-evaluation of Feed Additive Authorisations
Coccidiostat authorisations in the EU are granted for ten years and must be renewed on the basis of updated safety and efficacy data. Recent renewals show a trend towards tighter conditions: the 2026 renewal of Coxidin reduced the maximum content for chickens from 125 to 120 mg/kg and introduced resistance monitoring, while the 2023 authorisation of Avatec 150 G covered chickens for fattening but not chickens reared for laying. Each renewal requires investment in dossiers and studies, which favours established suppliers and raises barriers for smaller producers.
The ionophores value chain extends from fermentation inputs to the livestock producers who use medicated feed. Value is added mainly in fermentation and formulation, where yield, purity and registration status determine cost position and market access.
Raw Materials and Inputs
Ionophores are produced by submerged fermentation of selected Streptomyces and Actinomadura strains. The main inputs are carbohydrate sources such as corn starch and glucose, nitrogen sources such as soybean meal, vegetable oils, mineral salts, and energy and water. Proprietary high-yield production strains are a key cost and quality factor. Carriers such as calcium carbonate, rice hulls or wheat middlings are used in premix formulation.
Manufacturing
Manufacturing involves fermentation, recovery of the active ingredient (often as mycelial biomass or purified sodium salt), drying and formulation into premixes or granular products with standardised potency, such as 20% monensin or 12% salinomycin. Producers must meet good manufacturing practice requirements and hold product-specific registrations in each market. Major production sites include Elanco’s fermentation plant in Clinton, Indiana; Huvepharma’s facilities in Bulgaria; and fermentation plants operated by Chinese producers in Inner Mongolia and Shandong.
Distribution and Channels
Finished products reach the market through the sales organisations of animal health companies, national distributors and premix manufacturers. Large poultry integrators and feedlots often buy directly from manufacturers under annual supply agreements and incorporate the ionophore in their own feed mills. Smaller producers obtain ionophores through commercial feed mills, which include them in complete feed or supplements. Technical service from veterinarians and nutritionists is an important part of the offer, particularly for designing rotation programmes.
End Users
End users are broiler and turkey integrators, broiler breeder and pullet operations, beef feedlots, backgrounding and pasture cattle operations, and dairy farms. Poultry integrators use ionophores mainly in starter and grower feeds for coccidiosis prevention, while cattle producers use them throughout the feeding period to improve feed efficiency and prevent digestive disorders.
North America: In the U.S., ionophores are approved by the FDA as new animal drugs for use in medicated feed. They are classified as not medically important, so they are not subject to the Veterinary Feed Directive, and the revised Guidance for Industry #152, finalised in August 2026, continues this treatment. Feed manufacturers must follow current good manufacturing practice, including 21 CFR 225.65 on equipment cleanout and sequencing. The USDA FSIS guideline on animal-raising claims determines whether products can be labelled “raised without antibiotics”, and ionophore use rules out such claims. In Canada, the CFIA Compendium of Medicating Ingredient Brochures specifies approved uses, inclusion levels and warnings, including the prohibition of access by horses and dogs to monensin-containing feed.
Europe: In the EU, coccidiostats are authorised as feed additives under Regulation (EC) No 1831/2003, following an evaluation by EFSA’s FEEDAP Panel. Authorisations are granted to a named holder for a specific product and species, for ten years. Growth-promoting uses of monensin sodium and salinomycin sodium were withdrawn from 1 January 2006. Recent product-specific acts include Implementing Regulation (EU) 2023/1172 for Avatec 150 G (lasalocid), (EU) 2026/532 renewing Coxidin (monensin) and (EU) 2026/1860 for Monteban G100 (narasin). Carry-over into non-target feed is limited by Regulation (EC) No 124/2009 and Directive 2009/8/EC. Veterinary medicinal products containing ionophores, such as intraruminal devices, fall under Regulation (EU) 2019/6. In Great Britain, the assimilated feed additive rules apply, with the VMD regulating specified feed additives.
Asia Pacific: In China, MARA Announcement No. 194 withdrew growth-promoting drug feed additives from 1 January 2020 and required feed mills to stop producing commercial feed containing them from 1 July 2020. Anticoccidials were converted from feed-additive approval numbers to veterinary drug approval numbers and remain usable in commercial feed. In Australia, ionophores are registered by the APVMA, and ASTAG rates them as of low importance to human health. In India, the 2019 ban on colistin and the FSSAI residue regulations effective April 2025 target specified antibiotics in food animals.
Latin America: In Brazil, Portaria SDA/MAPA No. 1.617 of April 2026 banned five antimicrobial growth promoters (avoparcin, bacitracin, zinc bacitracin, bacitracin methylene disalicylate and virginiamycin), without including ionophores. Product registration across Latin America is managed by national agriculture ministries.
Middle East & Africa: In South Africa, ionophore feed additives are registered under the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947). Gulf Cooperation Council markets regulate veterinary products and feed additives through national ministries and municipal authorities.
Jun 2023: Phibro Animal Health; Regulatory approval; Commission Implementing Regulation (EU) 2023/1172 authorised Avatec 150 G (lasalocid A sodium) for chickens for fattening, with Phibro Animal Health S.A. as holder.
Jul 2023: Tyson Foods; Policy change; Announced the move of its branded chicken from “No Antibiotics Ever” to “No Antibiotics Important to Human Medicine”, allowing the use of ionophores, with completion planned by the end of 2023.
Sep 2023: Jinhe Biotechnology; Capacity expansion; Announced that a new chemical products plant would be completed by the end of 2023 and start production in the first half of 2024, doubling chemical capacity; the company’s chemical product line includes salinomycin and monensin.
Mar 2024: Chick-fil-A; Policy change; Announced a move to a “No Antibiotics Important to Human Medicine” standard for its chicken from spring 2024.
Apr 2024: Phibro Animal Health / Zoetis; Acquisition agreement; Phibro agreed to acquire the Zoetis medicated feed additive portfolio and certain water-soluble products for USD 350 million, covering more than 37 product lines sold in about 80 countries and six manufacturing sites.
May 2024: Elanco Animal Health; Regulatory action; The European Commission suspended the EU marketing authorisation of Kexxtone (monensin intraruminal device for dairy cows) following a quality defect.
May 2024: Elanco Animal Health; Product approval; The U.S. FDA completed its review of Bovaer, a methane-reducing feed ingredient for dairy cattle distributed by Elanco, extending its cattle feed additive portfolio.
Oct 2024: Phibro Animal Health; Acquisition completed; Completed the acquisition of the Zoetis medicated feed additive portfolio and certain water-soluble products, expanding its medicated feed additive business.
Mar 2026: Huvepharma; Regulatory renewal; Commission Implementing Regulation (EU) 2026/532 renewed the authorisation of Coxidin (monensin sodium) and extended it to chickens reared for laying, turkeys for fattening and breeding turkeys.
Apr 2026: Elanco Animal Health; Acquisition; Completed the acquisition of AHV International B.V. to strengthen its farm animal portfolio, particularly for cattle.
May 2026: Huvepharma; Product update; Coxidin obtained a zero-day withdrawal period in Europe following the renewal of its brand-specific authorisation.
Jul 2026: Elanco Animal Health; Regulatory approval; Commission Implementing Regulation (EU) 2026/1860 authorised Monteban G100 (narasin) for chickens for fattening, with Elanco GmbH as holder.
Near-term growth will likely concentrate in modular bioreactor lines and closed-system media workflows that shorten validation cycles while preserving batch traceability.
Partnerships between CDMOs and instrumentation vendors should accelerate standard datasets for comparability across sites, improving forecasting models used in capacity planning.
Longer horizon, organoid and microphysiological adoption may reshape segment mix; teams that invest early in assay interoperability and cloud QC hooks are better positioned to capture upside without fragmenting their analytics stack.
Profiles of 30 companies operating in the Ionophores Market market, including revenue, employee count, and market positioning where available.
Showing 30 of 30 companies
Company Headquarters: Carros, Southeastern France, France Founded: 1968 Workforce: ~4825 Company Working: Virbac develops, manufactures, and markets a wide range of veterinary pharmaceutical products and has a market experience of more than fifty years and is one of the top 10 players in the global animal health market. It operates through the livestock and aquaculture business segments, and manufactures products including parasiticides, immunology, antibiotics/dermatology, specialties, equine, and specialized pet food. The company has a presence in more than 100 countries and generates more than 60% of its revenue from outside Europe. It has 11 manufacturing units in different countries and five fully equipped R&D facilities for the development of products.
3 interactive charts drawn from the Ionophores Market dataset — market size, regional splits and each segment breakdown. Open one to read its full data table and download it.
Global Ionophores Market By Livestock
Global Ionophores Market By Product Type
Global Ionophores Market By Region
Powering the world's best teams.
From next-gen startups to established enterprises.
Trusted by forward-thinking businesses
for data-driven intelligence
Co-Founder, Mojave Rail Fabrication Limited
This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.
Manager, JavolVision
Thanks, I am so happy that we worked together. Maybe we still can work together in the future.
Sales Operations & Pricing Manager, Intel
Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.
Sales Leader, Bamberg
We bought your "2025 report" in 2020. Everything is fine and very good.
Account and Business Manager, EFS-Holland BV
Thanks for sending the report it gives us a good global view of the Betaïne market.
Senior Retail Manager, LG Chem
We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.
Management Consultant, Level 21
I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.
Group Product Manager HVAC & Fire Protection GMA, Rockwool
I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!
R&D Director, Seojin
Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.
Strategy & Business Development Director, Dogan Holding
We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.
Historical performance and future projections (2020–2030, USD Billion)
Market Size (USD Million)
